Johnson & Johnson (NYSE:JNJ), a global healthcare giant, continues to navigate a complex landscape of opportunities and ...

Whether Ben Johnson and Ryan Poles think it's a top priority isn't known but the new Bears coach threw out a position they could stand to 'augment.' ...

Ben Johnson doesn't need clichés to get his point across, nor does he want anything that he didn't earn. He's the right guy for the Chicago Bears. What's better is that he knows it, too.

With more than $85 billion in revenue, Johnson & Johnson is among the world’s top pharmaceutical companies. And with that industry dominance comes a slew of challenges relating to supply chain ...

Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

Stifel analyst Rick Wise lowered the firm’s price target on Johnson & Johnson to $155 from $170 and keeps a Hold rating on the shares.

Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...